Data-verified, healthier buildings
The MicrobX™ program, from Science-Proven Microbial Control®, treats surfaces to protect in a three-phase Assess-Act-Audit program
Touchpoint Protection
“With infections spread through touching surfaces, ATMs must remain pathogen free. MicrobX helps us do that.”
Michael Wolnerman, RPh, CCIM, President
Pharmco Properties
ASSESS
The MicrobX program starts with a baseline test to determine the current bioburden levels on common touchpoints by measuring Adenosine Triphosphate (ATP).
ATP is the energy molecule found in all living things, and its presence indicates the level of bacterial contaminant and freedom from virulent microbes.
The initial test provides measurements that are used for future numerical comparisons of the protectant’s efficacy.
ACT
After a pre-treatment disinfection with an EPA List-N disinfectant, a surface protectant is applied by electrostatic sprayer.
The application creates a positive electrical charge of the protectant’s particles that aggressively cling to the front, back, and sides of surfaces.
AUDIT
Regularly scheduled touchpoint testing tracks the protectant’s efficacy and provides verifiable proof. Reports are provided from data in the MicrobX cloud technology.
For occupants’ confidence in the health of their building, scanned QR codes lead to landing pages that show the last test date, its “pass/fail” status, and the next scheduled test. “Pass” status is achieved by maintaining stringently low levels of bioburden.
Window and mirror decals are visual reminders that your building’s touchpoints are protected against the spread of infections.
Website Disclaimer:
Although the application of an EPA – registered (“List-N”) disinfectant to kill viruses (including COVID-19) is the first step of the MicrobX program, no antimicrobial surface protectant (including that used in the MicrobX program) has yet been registered by the EPA as effective in preventing the transmission of viruses, including Coronavirus (COVID-19), or the transmission of infections.